Sight Sciences presents Q3 revenue growth of 25% to $24.9 million
SGHT•Sight Sciences reported third-quarter 2026 revenue of $24.9 million, up 25% year over year, while quarterly cash usage fell 74% to $2.4 million.
1. Quarterly results
Sight Sciences reported third-quarter 2026 revenue of $24.9 million, up 25% year over year. Quarterly cash usage fell 74% to $2.4 million.
2. Year-to-date figures
Year-to-date revenue rose 19% to $68 million, while adjusted operating expenses declined 2% to $67.5 million. Interventional glaucoma revenue increased 7% to $60.1 million, and interventional dry eye revenue reached $7.9 million, compared with $0.9 million a year earlier.
